Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A6LT
|
|||
| Former ID |
DIB015709
|
|||
| Drug Name |
PEG-bHb-CO
|
|||
| Synonyms |
Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals
Click to Show/Hide
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 2/3 | [1] | |
| Cerebral ischemia [ICD-11: 8B11; ICD-10: I67.8] | Phase 2 | [2] | ||
| Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57.0; ICD-9: 282.6] | Phase 2 | [3] | ||
| Company |
Prolong Pharmaceuticals Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02490202) Efficacy and Safety of SANGUINATE for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.